AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38109921 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 2-week interval (group B)
Number of subjects: 905
Study 38109921 — intervention group
Group type: COMPARATOR
Intervention: nOPV2 vaccine administered at a 0.1 mL dose with a 4-week interval (group C)
Number of subjects: 905
Study 38109921 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group B (2-week interval) to group C (4-week interval)
Number of subjects: 905
Study 38109921 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A (1-week interval) to group C (4-week interval)
Number of subjects: 905
Study 38109921 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 2 doses of nOPV2
Number of subjects: 905
Study 38109921 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2 vaccine
Number of subjects: 905
Study 38109916 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 690517 (aldosterone synthase inhibitor)
Number of subjects: 586
Study 38109916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 38109984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg QD
Number of subjects: 1000
Study 38109984 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg QD
Number of subjects: 1000
Study 38109984 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg QD
Number of subjects: 1000
Study 38109984 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 25 mg BID
Number of subjects: 1000
Study 38110039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese heart-healthy (CHH) diet
Number of subjects: 256
Study 38110039 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control)
Number of subjects: 256
Study 38110144 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS with tele-support
Number of subjects: 42
Study 38110144 — intervention group
Group type: COMPARATOR
Intervention: POCUS without tele-support
Number of subjects: 42
Study 38110144 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS (both groups)
Number of subjects: 42
Study 38110180 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (BRJ)
Number of subjects: 8
Study 38110180 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitrate (NIT)
Number of subjects: 8
Study 38110181 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary potassium concentrations in Black participants
Number of subjects: 790
Study 38110181 — intervention group
Group type: COMPARATOR
Intervention: Urinary potassium in White adults
Number of subjects: 790
Study 38110181 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated C0-, C3-, and C5-carnitine
Number of subjects: 790
Study 38110183 — intervention group
Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (school-based gardening, cooking, and nutrition trial)
Number of subjects: 619
Study 38110183 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity at baseline to food secure at follow-up
Number of subjects: 619
Study 38110183 — intervention group
Group type: COMPARATOR
Intervention: Remained food insecure throughout
Number of subjects: 619
Study 38110183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-point increase in food insecurity
Number of subjects: 619
Study 38110196 — intervention group
Group type: EXPERIMENTAL
Intervention: Voclosporin (23.7 mg twice daily)
Number of subjects: 148
Study 38110196 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 148
Study 38110372 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 panel (HABP2, CD163, AFP and PIVKA-II)
Number of subjects: 1002
Study 38110376 — intervention group
Group type: EXPERIMENTAL
Intervention: Care cOORDInatioN And sympTom managEment (COORDINATE) intervention
Number of subjects: 0
Study 38110389 — intervention group
Group type: EXPERIMENTAL
Intervention: NSTEMI patients
Number of subjects: 8277
Study 38110389 — intervention group
Group type: COMPARATOR
Intervention: STEMI patients
Number of subjects: 8277
Study 38110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation plus standard of care
Number of subjects: 0
Study 38110392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfer plus standard of care
Number of subjects: 0
Study 38110392 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study 38110561 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day for 21-28 days
Number of subjects: 61
Study 38110561 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 61
Study 38110580 — intervention group
Group type: EXPERIMENTAL
Intervention: ePOCT+
Number of subjects: 44306
Study 38110653 — intervention group
Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 165
Study 38110665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 15 mg/kg Q3W plus anlotinib
Number of subjects: 69
Study 38110665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg Q3W plus anlotinib
Number of subjects: 69
Study 38110790 — intervention group
Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599); orally administered small molecule inhibitor of ASYN misfolding; specific dosage and duration not mentioned.
Number of subjects: 0
Study 38110790 — intervention group
Group type: EXPERIMENTAL
Intervention: N-methyl labeled PET tracer; specific dosage and duration not mentioned.
Number of subjects: 0
Study 38110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal sleep difficulties
Number of subjects: 1238
Study 38110851 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-year follow-up
Number of subjects: 1238
Study 38110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of depressed mood
Number of subjects: 1238
Study 38110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic and environmental factors
Number of subjects: 1238
Study 38110851 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal relationship
Number of subjects: 1238
Study 38110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir for 12 weeks (extended to 24 weeks for those with cirrhosis)
Number of subjects: 25000
Study 38110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and daclatasvir treatment
Number of subjects: 25000
Study 38110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for new HCV infections 12 months later
Number of subjects: 25000
Study 38110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing risk factors, productivity, health care usage, and quality of life
Number of subjects: 25000
Study 38110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Retesting patients who completed treatment 12 months later
Number of subjects: 25000
Study 38110901 — intervention group
Group type: EXPERIMENTAL
Intervention: HIP1601 (dual delayed-release esomeprazole) 40 mg
Number of subjects: 213
Study 38110901 — intervention group
Group type: COMPARATOR
Intervention: HGP1705 (delayed-release esomeprazole) 40 mg
Number of subjects: 213
Study 38110921 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prepregnancy BMI ≥ 25 kg/m²
Number of subjects: 24294
Study 38110921 — intervention group
Group type: COMPARATOR
Intervention: BMI reference group (control)
Number of subjects: 24294
Study 38110922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program
Number of subjects: 34
Study 38110922 — intervention group
Group type: COMPARATOR
Intervention: Standard care exercise
Number of subjects: 34
Study 38110937 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally 3D-printed ocular prostheses (DG, n=11)
Number of subjects: 22
Study 38110937 — intervention group
Group type: COMPARATOR
Intervention: Conventional PMMA ocular prostheses (CG, n=11)
Number of subjects: 22
Study 38110937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DG and CG)
Number of subjects: 22
Study 38110937 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed acrylic resin (DG)
Number of subjects: 22
Study 38110979 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard implementation approach (online training, live webinar, resource website)
Number of subjects: 30
Study 38110979 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual facilitation approach (provided by a trained facilitator)
Number of subjects: 30
Study 38110997 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on de-escalation of violence and a code of conduct informed through participatory citizen science research
Number of subjects: 11
Study 38110997 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 11
Study 38110997 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on de-escalation of violence and a code of conduct
Number of subjects: 11
Study 38110997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness study comparing the two strategies
Number of subjects: 11
Study 38111533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide + Velcade + Dexamethasone (PVd)
Number of subjects: 186
Study 38111533 — intervention group
Group type: COMPARATOR
Intervention: Velcade + Dexamethasone (Vd)
Number of subjects: 186
Study 38111608 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbracePlus wristband
Number of subjects: 15
Study 38111676 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-belt treadmill mode at comfortable walking speed (CWS)
Number of subjects: 18
Study 38111676 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-belt treadmill mode with backward-directed resistance
Number of subjects: 18
Study 38111699 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 0.2% flushing of suctioning catheters after every endotracheal suction procedure
Number of subjects: 136
Study 38111699 — intervention group
Group type: COMPARATOR
Intervention: Normal saline or distilled water flushing of suctioning catheters
Number of subjects: 136
Study 38111750 — intervention group
Group type: EXPERIMENTAL
Intervention: Casirivimab and imdevimab
Number of subjects: 1069
Study 38111750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1069
Study 38111750 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral loads (∼6.0 log)
Number of subjects: 1069
Study 38111886 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) during AC including the provision of an activity tracker
Number of subjects: 57
Study 38111886 — intervention group
Group type: COMPARATOR
Intervention: Control group (EXpostAC) received an activity tracker only
Number of subjects: 57
Study 38111994 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention programme
Number of subjects: 297
Study 38111994 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 297
Study 38112484 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.4 mg
Number of subjects: 251
Study 38112493 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified rooms
Number of subjects: 74
Study 38112493 — intervention group
Group type: COMPARATOR
Intervention: Standard rooms
Number of subjects: 74
Study 38112493 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity
Number of subjects: 74
Study 38112493 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in serum melatonin
Number of subjects: 74
Study 38112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids used as an adjunct to antimicrobial therapy for herpetic keratitis
Number of subjects: 0
Study 38112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids used as an adjunct to antimicrobial therapy for bacterial keratitis
Number of subjects: 0
Study 38112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for advanced bacterial corneal ulcers
Number of subjects: 0
Study 38112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for fungal keratitis
Number of subjects: 0
Study 38112645 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids for acanthamoeba keratitis
Number of subjects: 0
Study 38112724 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic intervention
Number of subjects: 0
Study 38112795 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pomalidomide (4 mg daily on days 1-21) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22; 20 mg for patients aged > 75 years)
Number of subjects: 85
Study 38112795 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pomalidomide plus low-dose dexamethasone
Number of subjects: 85
Study 38112814 — intervention group
Group type: EXPERIMENTAL
Intervention: AI model predictions without explanations
Number of subjects: 457
Study 38112814 — intervention group
Group type: EXPERIMENTAL
Intervention: AI model predictions with explanations
Number of subjects: 457
Study 38112814 — intervention group
Group type: COMPARATOR
Intervention: Systematically biased AI model predictions
Number of subjects: 457
Study 38112814 — intervention group
Group type: COMPARATOR
Intervention: Biased AI model predictions with explanations
Number of subjects: 457
Study 38112922 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg, twice daily)
Number of subjects: 256
Study 38113009 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized plan (PP) with personalized home-delivered meals and behavioral change messages
Number of subjects: 0
Study 38113009 — intervention group
Group type: COMPARATOR
Intervention: Control group with non-personalized meals and messages
Number of subjects: 0
Study 38113009 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized plan (PP)
Number of subjects: 0
Study 38113022 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum Molecular Resonance (QMR) treatment, 4 sessions at 1-week intervals.
Number of subjects: 81
Study 38113022 — intervention group
Group type: COMPARATOR
Intervention: SH-TH group (control group).
Number of subjects: 81
Study 38113093 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational savoring (RS) intervention for 4 weeks
Number of subjects: 80
Study 38113093 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 80
Study 38113103 — intervention group
Group type: EXPERIMENTAL
Intervention: DrinksRation smartphone app intervention
Number of subjects: 0
Study 38113103 — intervention group
Group type: COMPARATOR
Intervention: UK Chief Medical Officer guidance on alcohol consumption (control)
Number of subjects: 0
Study 38113102 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirabo SMS text message intervention
Number of subjects: 200
Study 38113446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 15804
Study 38113446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15804
Study 38113446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day) in participants with <12 ng/mL and denied taking concurrent vitamin D
Number of subjects: 15804
Study 38113446 — intervention group
Group type: COMPARATOR
Intervention: Placebo in participants with <12 ng/mL and denied taking concurrent vitamin D
Number of subjects: 15804
Study 38113459 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg once daily (daily dosing group)
Number of subjects: 100
Study 38113459 — intervention group
Group type: COMPARATOR
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group)
Number of subjects: 100
Study 38113470 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax-R2 (venetoclax 600 mg daily after ramp-up, lenalidomide 20 mg daily for days 1 to 21, rituximab 375 mg/m2 weekly for 4 weeks then every 8 weeks)
Number of subjects: 59
Study 38113483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention involving traditional marine foods
Number of subjects: 0
Study 38113483 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming sucrose- and starch-rich foods
Number of subjects: 0
Study 38113746 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-treated patients
Number of subjects: 69
Study 38113746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-treated patients
Number of subjects: 69
Study 38113746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-isolated COVID-19 patients
Number of subjects: 69
Study 38113746 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 controls
Number of subjects: 69
Study 38113919 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 96
Study 38113919 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptoms
Number of subjects: 96
Study 38114046 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site cardiac rehabilitation followed by 12 weeks of telerehabilitation
Number of subjects: 40
Study 38114046 — intervention group
Group type: COMPARATOR
Intervention: On-site cardiac rehabilitation followed by standard homecare and exercise programme
Number of subjects: 40
Study 38114277 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheterisation with a needle guide (n=150)
Number of subjects: 300
Study 38114277 — intervention group
Group type: COMPARATOR
Intervention: Catheterisation without a needle guide (n=150)
Number of subjects: 300
Study 38114357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Number of subjects: 228
Study 38114357 — intervention group
Group type: COMPARATOR
Intervention: Amivantamab
Number of subjects: 228
Study 38114507 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed personalized liver models based on self-healing elastomers
Number of subjects: 5
Study 38114518 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus stereotactic radiation (DRT)
Number of subjects: 0
Study 38114518 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab monotherapy
Number of subjects: 0
Study 38114518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (combined)
Number of subjects: 0
Study 38114596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of autologous bone marrow mononuclear cells (BMMNCs)
Number of subjects: 0
Study 38114596 — intervention group
Group type: COMPARATOR
Intervention: ASD patients
Number of subjects: 0
Study 38114596 — intervention group
Group type: COMPARATOR
Intervention: CP patients
Number of subjects: 0
Study 38114624 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945 at doses ranging from 64 mg/day to 128 mg/day
Number of subjects: 13
Study 38114624 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-400945
Number of subjects: 13
Study 38114718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) therapy cessation
Number of subjects: 57
Study 38114794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine supplementation
Number of subjects: 9
Study 38114794 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex- and age-matched)
Number of subjects: 9
Study 38114867 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Body Mass Index (BMI)
Number of subjects: 147
Study 38114867 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 147
Study 38114941 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal BIS sensor position
Number of subjects: 12
Study 38114941 — intervention group
Group type: COMPARATOR
Intervention: Post-auricular BIS sensor position
Number of subjects: 12
Study 38114941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sensor positions
Number of subjects: 12
Study 38114952 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO) therapy
Number of subjects: 60
Study 38114952 — intervention group
Group type: COMPARATOR
Intervention: Control (observing a natural landscape)
Number of subjects: 60
Study 38114958 — intervention group
Group type: EXPERIMENTAL
Intervention: Corega Ultra denture fixative cream (GlaxoSmithKline)
Number of subjects: 64
Study 38114958 — intervention group
Group type: EXPERIMENTAL
Intervention: Olivafix (Bonyf)
Number of subjects: 64
Study 38114958 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea.Bond adhesive strips (Sea.Bond)
Number of subjects: 64
Study 38114979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bis-GMA-free resin composite (Admira fusion x-tra)
Number of subjects: 20
Study 38114979 — intervention group
Group type: COMPARATOR
Intervention: Bis-GMA containing resin composite (x-tra fil)
Number of subjects: 20
Study 38115002 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 0
Study 38115002 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 0
Study 38115002 — intervention group
Group type: EXPERIMENTAL
Intervention: primaquine
Number of subjects: 0
Study 38115002 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping methods
Number of subjects: 0
Study 38115002 — intervention group
Group type: EXPERIMENTAL
Intervention: Early phase power calculations
Number of subjects: 0
Study 38115004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg daily)
Number of subjects: 14
Study 38115004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 38115038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative HMW microdialysis
Number of subjects: 14
Study 38115038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate-containing perfusate
Number of subjects: 14
Study 38115038 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin-containing perfusate
Number of subjects: 14
Study 38115195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab s.c. 720, 960, or 1,200 mg
Number of subjects: 82
Study 38115195 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab i.v. 3 mg/kg every 2 weeks
Number of subjects: 82
Study 38115195 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab i.v. 10 mg/kg every 2 weeks
Number of subjects: 82
Study 38115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib (300 mg once daily) plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 159
Study 38115208 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib (10 mg once daily in Part 1; 0.3 mg once daily in Part 2) plus pembrolizumab (200 mg every 3 weeks)
Number of subjects: 159
Study 38115209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tozorakimab (subcutaneous or intravenous)
Number of subjects: 88
Study 38115745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 53
Study 38115745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53